$131.70
0.000.00%
At close: -
$131.89
0.190.14%
After Hours: 5:42 PM EDT
Comments
Loading...
Intra-Cellular Therapies Earnings Estimates, EPS & Revenue | NASDAQ:ITCI | Benzinga
Intra-Cellular Therapies reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 6
EPS Estimate
$-0.170
Quarterly Revenue Estimate
$198.77M
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$680.50M
Analyze the earnings history of Intra-Cellular Therapies using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ITCI | Intra-Cellular Therapies | -$0.16 | -$0.17 | — | — | $144.87M | $198.77M | — | — | 05/06/2025 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.29 | -$0.12 | -$0.16 | -33.33% | $132.10M | $193.96M | $199.22M | 2.71% | 02/21/2025 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.25 | -$0.20 | -$0.25 | -25.00% | $126.17M | $172.35M | $175.38M | 1.76% | 10/30/2024 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.45 | -$0.19 | -$0.16 | 15.79% | $110.79M | $157.88M | $161.39M | 2.22% | 08/07/2024 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.46 | -$0.33 | -$0.16 | 51.52% | $95.31M | $140.91M | $144.87M | 2.81% | 05/07/2024 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.45 | -$0.43 | -$0.30 | 30.23% | $87.87M | $136.79M | $132.10M | -3.43% | 02/22/2024 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.57 | -$0.56 | -$0.25 | 55.36% | $71.87M | $119.35M | $126.17M | 5.72% | 11/02/2023 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.92 | -$0.62 | -$0.45 | 27.42% | $55.58M | $106.56M | $110.79M | 3.97% | 08/03/2023 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.78 | -$0.60 | -$0.46 | 23.33% | $35.00M | $91.98M | $95.31M | 3.62% | 05/04/2023 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$1.05 | -$0.59 | -$0.45 | 23.73% | $25.67M | $86.97M | $87.87M | 1.03% | 03/01/2023 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.95 | -$0.81 | -$0.57 | 29.63% | $22.21M | $66.00M | $71.87M | 8.89% | 11/03/2022 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.85 | -$0.76 | -$0.92 | -21.05% | $20.05M | $49.02M | $55.58M | 13.38% | 08/09/2022 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.65 | -$0.92 | -$0.78 | 15.22% | $15.88M | $33.65M | $35.00M | 4.00% | 05/10/2022 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.76 | -$1.00 | -$1.05 | -5.00% | $12.45M | $25.37M | $25.67M | 1.19% | 03/01/2022 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.79 | -$0.92 | -$0.95 | -3.26% | $7.37M | $22.12M | $22.21M | 0.39% | 11/09/2021 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.96 | -$0.80 | -$0.85 | -6.25% | $1.91M | $19.44M | $20.05M | 3.12% | 08/09/2021 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.73 | -$0.80 | -$0.65 | 18.75% | $1.08M | $16.50M | $15.88M | -3.77% | 05/10/2021 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.74 | -$0.85 | -$0.76 | 10.59% | $60.61K | $11.84M | $12.45M | 5.19% | 02/25/2021 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.63 | -$1.00 | -$0.79 | 21.00% | $0.00 | $5.86M | $7.37M | 25.75% | 11/09/2020 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.68 | -$0.91 | -$0.96 | -5.49% | $0.00 | $3.03M | $1.91M | -37.06% | 08/10/2020 | Get Alert |
| ITCI | Intra-Cellular Therapies | -$0.63 | -$0.93 | -$0.73 | 21.51% | $0.00 | $1.44M | $1.08M | -24.79% | 05/07/2020 | Get Alert |
Intra-Cellular Therapies (ITCI) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-21 | $-0.16 | $-0.12 | -33.3 % |
| Q3 | 2024-10-30 | $-0.25 | $-0.20 | -25.0 % |
| Q2 | 2024-08-07 | $-0.16 | $-0.19 | 15.8 % |
| Q1 | 2024-05-07 | $-0.16 | $-0.33 | 51.5 % |
Intra-Cellular Therapies (ITCI) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-21 | $199.22M | $193.96M | 2.71 % |
| Q3 | 2024-10-30 | $175.38M | $172.35M | 1.76 % |
| Q2 | 2024-08-07 | $161.39M | $157.88M | 2.22 % |
| Q1 | 2024-05-07 | $144.87M | $140.91M | 2.81 % |
FAQ
When is Intra-Cellular Therapies (NASDAQ:ITCI) reporting earnings?
Intra-Cellular Therapies (ITCI) is scheduled to report earnings on May 6, 2025. The last reported earnings were for reported on February 21, 2025 for Q4.
What were the latest earnings per share (EPS) for Intra-Cellular Therapies (NASDAQ:ITCI)?
The Actual EPS was $-0.16, which missed the estimate of $-0.12.
What were Intra-Cellular Therapies’s (NASDAQ:ITCI) revenues?
The Actual Revenue was $199.2M, which beat the estimate of $194M.
Browse earnings estimates, EPS, and revenue on all stocks.